These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29170979)

  • 21. Adiposity in Juvenile Psoriatic Arthritis.
    Samad A; Stoll ML; Lavi I; Hsu JJ; Strand V; Robinson TN; Mellins ED; Zisman D;
    J Rheumatol; 2018 Mar; 45(3):411-418. PubMed ID: 29247150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of disability in a childhood-onset systemic lupus erythematosus cohort: results from the CARRA Legacy Registry.
    Hersh AO; Case SM; Son MB;
    Lupus; 2018 Mar; 27(3):494-500. PubMed ID: 29251171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA).
    Orandi AB; Baszis KW; Dharnidharka VR; Huber AM; Hoeltzel MF;
    Pediatr Rheumatol Online J; 2017 Sep; 15(1):71. PubMed ID: 28934971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool.
    Sanner H; Sjaastad I; Flatø B
    Rheumatology (Oxford); 2014 Sep; 53(9):1578-85. PubMed ID: 24692575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-Reported Outcomes Among Transition-Age Young Adults With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.
    Smitherman EA; Chahine RA; Bitencourt N; Rahman AKMF; Lawson EF; Chang JC;
    J Rheumatol; 2023 Jan; 50(1):98-106. PubMed ID: 36109074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis.
    Orandi AB; Dharnidharka VR; Al-Hammadi N; Baszis KW;
    Pediatr Rheumatol Online J; 2018 Dec; 16(1):84. PubMed ID: 30594206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Importance of aggressive treatment in juvenile dermatomyositis].
    Vojinović J; Riley P; Maillard S; Pilkington C
    Srp Arh Celok Lek; 2005 Dec; 133 Suppl 2():118-23. PubMed ID: 16535995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases.
    Sato JO; Sallum AM; Ferriani VP; Marini R; Sacchetti SB; Okuda EM; Carvalho JF; Pereira RM; Len CA; Terreri MT; Lotufo SA; Romanelli PR; Ramos VC; Hilario MO; Silva CA; Corrente JE; Saad-Magalhães C;
    Clin Exp Rheumatol; 2009; 27(6):1031-8. PubMed ID: 20149327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Demographic, clinical, and treatment characteristics of the juvenile primary fibromyalgia syndrome cohort enrolled in the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.
    Weiss JE; Schikler KN; Boneparth AD; Connelly M;
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):51. PubMed ID: 31349785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Race, ethnicity, and disease outcomes in juvenile idiopathic arthritis: a cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry.
    Ringold S; Beukelman T; Nigrovic PA; Kimura Y;
    J Rheumatol; 2013 Jun; 40(6):936-42. PubMed ID: 23588937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group.
    Lovell DJ; Lindsley CB; Rennebohm RM; Ballinger SH; Bowyer SL; Giannini EH; Hicks JE; Levinson JE; Mier R; Pachman LM; Passo MH; Perez MD; Reed AM; Schikler KN; Smith M; Zemel LS; Rider LG
    Arthritis Rheum; 1999 Oct; 42(10):2213-9. PubMed ID: 10524696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey.
    Stringer E; Bohnsack J; Bowyer SL; Griffin TA; Huber AM; Lang B; Lindsley CB; Ota S; Pilkington C; Reed AM; Scuccimarri R; Feldman BM
    J Rheumatol; 2010 Sep; 37(9):1953-61. PubMed ID: 20595275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies.
    Huber AM; Feldman BM; Rennebohm RM; Hicks JE; Lindsley CB; Perez MD; Zemel LS; Wallace CA; Ballinger SH; Passo MH; Reed AM; Summers RM; White PH; Katona IM; Miller FW; Lachenbruch PA; Rider LG;
    Arthritis Rheum; 2004 May; 50(5):1595-603. PubMed ID: 15146430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis.
    Lazarevic D; Pistorio A; Palmisani E; Miettunen P; Ravelli A; Pilkington C; Wulffraat NM; Malattia C; Garay SM; Hofer M; Quartier P; Dolezalova P; Penades IC; Ferriani VP; Ganser G; Kasapcopur O; Melo-Gomes JA; Reed AM; Wierzbowska M; Rider LG; Martini A; Ruperto N;
    Ann Rheum Dis; 2013 May; 72(5):686-93. PubMed ID: 22736096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcome in children with juvenile dermatomyositis: A single-center study from north India.
    Sharma A; Gupta A; Rawat A; Suri D; Singh S
    Int J Rheum Dis; 2020 Mar; 23(3):392-396. PubMed ID: 31793219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of achievement of a full score on the childhood myositis assessment scale by healthy four-year-olds and those recovering from juvenile dermatomyositis.
    Quiñones R; Morgan GA; Amoruso M; Field R; Huang CC; Pachman LM
    Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1697-701. PubMed ID: 23666925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis.
    Schmeling H; Stephens S; Goia C; Manlhiot C; Schneider R; Luthra S; Stringer E; Feldman BM
    Rheumatology (Oxford); 2011 May; 50(5):885-93. PubMed ID: 21156669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care.
    Varnier GC; Rosina S; Ferrari C; Pistorio A; Consolaro A; Bovis F; Dalprà S; Pilkington C; Maillard S; Civino A; Tsitsami E; de Inocencio J; Jelusic M; Vojinovic J; Espada G; Makay B; Katsicas MM; Pratsidou-Gertsi P; Lazarevic D; Rao AP; Marafon DP; Ruperto N; Martini A; Ravelli A
    Arthritis Care Res (Hoboken); 2018 Sep; 70(9):1312-1319. PubMed ID: 29245175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr.
    McCann LJ; Juggins AD; Maillard SM; Wedderburn LR; Davidson JE; Murray KJ; Pilkington CA;
    Rheumatology (Oxford); 2006 Oct; 45(10):1255-60. PubMed ID: 16567354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept.
    Klotsche J; Minden K; Thon A; Ganser G; Urban A; Horneff G
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):253-62. PubMed ID: 23983081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.